Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.74 |
| ▸ | RAB9A | P51151 | 8/20 | 0.74 |
| ▸ | NPC1 | O15118 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | STAT1 | P42224 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.57 |
| ▸ | RELA | Q04206 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210881 | 1.00 | ALDH1A1 (0.74) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL7204653 | 0.93 | ALDH1A1 (0.65) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL7204650 | 0.93 | ALDH1A1 (0.65) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL4432835 | 0.86 | RAB9A (0.56) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL4432837 | 0.86 | RAB9A (0.56) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL28195698 | 0.85 | ALDH1A1 (0.74) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL13556270 | 0.81 | RAB9A (0.72) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL7203952 | 0.80 | POLB (0.53) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL7203950 | 0.80 | POLB (0.53) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL1590018 | 0.77 | ALDH1A1 (0.69) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0970079-B1 | FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-01 | — | — | EP | disclosed |
| US-6444812-B1 | SUCH AS 7-(3-CHLOROPHENYL)-9-((4-CHLOROPHENYL)-1H-IMIDAZOL-1-YLMETHYL)-2,3-DIHYDRO -1H,5H-BENZO(IJ) QUINOLIZIN-5-ONE; FOR FORMING ONCOGENES FOR SIGNALLING TRANSFORMATION OF TUMOR CELLS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-09-03 | — | — | US | disclosed |
| US-20020049327-A1 | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles | VENET MARC GASTON (FR) | 2002-04-25 | — | — | US | disclosed |
| US-6187786-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049327-A1 | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles | HCCS, CYP7A1, DHCR7 | ALDH1A1 533/4885RAB9A 917/4885NPC1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.